Expression of NK (CD16+56+) and B cells (CD19) Receptor Molecules as a Reliable Clinical Response Biomarkers

1. INTRODUCTION

Early response biomarkers of SLE and RA patients under the rituximab treatment are still in research phase and each new investigations offer new and original useful data. Due fact that, the leukocyte cell subpopulations analyzes of peripheral blood specimens taken from SLE and RA patients under rituximab treatment, are under intensively researches. For this purpose, the method of choice is immunophenotypization by flow cytometry Usually, analyses take place 6 weeks before and after rituximab intake based on doctor’s evaluation. Rituximab depletes already increased number of NK cells and CD19+ B-cells. CD20 antigen is found on surface of B lymphocytes and it is main binding site for rituximab which is a CD20-directed, IgG1-chimeric monoclonal antibody (mAb). Natural Killer (NK) cells constitute approximately 15% of the peripheral blood ant they expressed specific CD16 (FcYRIIA- Fragment crystallizable region, RIIIA), CD56 molecules and receptors for activation an inhibition. The main phenotype of NK cells is CD3 CD16+CD56+. Antibody dependent cellular cytotoxicity (ADCC) mediated by NK cells, may be a primary mechanism of Rituximab functions. Furthermore, responses to rituximab is depend on CD16 molecule polymorphisms. Activation of NK cells begins by binding CD16+ receptor for Fc region IgG molecules in antigen-antibody complex. This activation mediates antibody-dependent cellular cytotoxicity (ADCC). However, CD16+ receptor can be linked to free circulating IgG antibody causing inhibition of NK cell functions (1-3).

FCYRIIA gen encodes for CD16+ and is located on chromosome 1. Mutations in this gene have been linked to susceptibility to recurrent viral infections, susceptibility to systemic lupus erythematosus, and alloimmune neonatal neutropenia. In the case of lower expression of this gene, not enough amount of CD16...
Expression of NK (CD16+56+) and B cells (CD19) Receptor Molecules as a Reliable Clinical Response Biomarkers

2. AIM

Aim of article was to investigate by flow cytometric analyses expression of NK and CD19+ cells at SLE and RA patients before and after treatment with rituximab.

3. METHODS

Blood collection
Based on clinical and laboratory parameters, doctors rheumatologist selected patients for further analyses. Their blood was collected into EDTA Vacutainer tubes and transpnted to the Flow cytometry laboratory of Department of Clinical immunology in the Clinical Centre University of Sarajevo. Ethical approval was obtained from Ethical Committee Clinical Center University of Sarajevo.

Flow cytometry
Flow cytometry is multiparametric analysis of morphological, biochemical and functional cell features with diameter in range of 0.2-150 µm. By flow cytometry is possible to determine the frequency of T lymphocytes (CD3+, CD4+, CD8+, CD4+/CD8+ ratio), B lymphocytes (CD19+), NK cells (CD16+CD56+), activated lymphocytes (CD8+CD38+) and absolute number of CD4+ T and CD8+ T lymphocytes.

Immunophenotyping of cells was carried out by a standard method of sample preparation. After lysis of erythrocytes, the leukocytes of peripheral blood were analyzed for the expression of specific leukocyte markers using a panel of monoclonal antibodies and flow cytometry (flow cytometer–BD FACS Canto II). 10,000-50,000 events were recorded per tube and analyzed using the BD FACSDiva™ software. The best results will be achieved if analysis of the cells on the flow cytometer are performed as soon as possible.

Monoclonal Antibodies
Combinations of surface markers that are determined by monoclonal antibody conjugated with FITC (i.e. fluorescin isothiocyanate), PE (i.e. phycoerythrin) and PerCP (i.e. Peridinin-chlorophyll-protein complex) or APC (i.e. aolifocianin) (9,10,11) as follows:

- Tube 1: CD3–FITC/ CD8–PE/ CD45–PerCP/ CD4–APC;
- Tube 2: CD3 – FITC / CD16+56–PE/ CD45–PerCP/ CD19–APC.

4. RESULTS

Percentages of CD16 and CD19 receptor molecules on NK cells and B lymphocytes obtained by immunophenotypisation analyses were the main guidance of treatment efficiency.

The number of peripheral blood CD16+56 NK cells and CD19+ B cells were analyzed by flow cytometry. We analyzed 10 samples with SLE diagnosis and 5 samples with RA diagnosis.

### Table 1. Obtained results of immunophenotypization analyses for 10 SLE patient specimens

| Sample | CD19+ (B Ly) | CD16+56 (NK) |
|--------|-------------|--------------|
| Referral values (%) | 6.4–23 | 5.6–31 |
| Sample 1 | 6.8 | 6.8 |
| Sample 2 | 2.0 | 8.6 |
| Sample 3 | 6.3 | 3.5 |
| Sample 4 | 2.0 | 6.2 |
| Sample 5 | 0.9 | 4.1 |
| Sample 6 | 12.1 | 9.7 |
| Sample 7 | 24.1 | 5.9 |
| Sample 8 | 26.5 | 13.5 |
| Sample 9 | 36.3 | 0.6 |
| Sample 10 | 24.8 | 1.3 |

### Table 2. Obtained number of immunophenotypization analyses for 5 RA patient specimens

| Sample | CD19+ (B Ly) | CD16+56 (NK) |
|--------|-------------|--------------|
| Referral values (%) | 6.4-23 | 5.6-31 |
| Sample 1 | 23.2 | 9.0 |
| Sample 2 | 6.4 | 5.1 |
| Sample 3 | 22.9 | 19.0 |
| Sample 4 | 11.2 | 22.0 |
| Sample 5 | 14.6 | 8.6 |

![Figure 1. Samples of RA patients. Treatment with rituximab proved to be successful within the majority of specimens expect sample 2](image-url)

Out of 5 samples selected for biological therapy sample 1 showed increased number of CD19+ parameter while sample 3 showed slightly lower number of it. Oth-
seriously increased number of CD19+ B cells. From these results we can conclude that the worst results had samples 9 and 10.

In both cases, SLE and RA patients, reduced number of CD16+ parameter indicates lower cytotoxic activity of NK cells. Those kind of NK cells have reduced ability of binding with immune complex connected with antigens and therefore their ADCC activity is reduced. Increased number of B cells indicates higher pathological activity leading to severe autoimmune disease allegation.

5. DISCUSSION

Today is a era if biological drugs. One of the most important of them is Rituximab, a monoclonal recombinant antibody strongly specific to B cell CD20 receptor molecules. In fact, the active place for rituximab adhesion is placed on extracellular region these molecules. CD20 molecules must have normal conformation but in contrary, in the case of specific mutation of CD20 gene, this active region can missed. However, CD20 human gene is placed on 11 chromosome (11q12-q13.1) and has 8 exons in coding region (E1,E2, E3, E4, E5, E6, E7, E8).

This gene coding three mRNA splice isoforms or variants. The dominant CD20 mRNA isoform has all exons, but minor isoform is without 3-7 exons and final translational product have no active place specific for rituximab (7, 8, 9). Because of that, before rituximab therapy, it is necessary to perform molecular selection of patients by PCR detection of CD20 splice variant. Minor splice CD20 mRNA isoform is not feature of healthy persons but only appeared in pathological cases such as autoimmune disorders, lymphomas or malignant diseases. This splice form can be unique biomarker in the selection of biological drugs in rheumatology. However, molecular-genetic predictive rheumatological diagnostics is based on determination of specific genetic and epigenetic biomarkers. According to obtained data it is possible to select the most effective drug for each patient personally. On this way it is possible to avoid unnecessary costs and increase the effectiveness of the therapy to the highest possible level (10, 11).

Rituximab has wide application in clinical management of rheumatic disorders such as for example Rheumatic arthritis (RA). These specific monoclonal antibodies recognize CD20 active sites on B cells, and then, these rituximab-coated B cells, are lyzing by NK cells. On this way, is possible to achieve desired therapeutic depletion of B cells. The rituximab-induced phenomenon of B cells depletion by NK cells activity is object of many investigations.

However, NK cells are actually cytotoxic lymphocytes targeted specially to antibody coated cells, but until now, there is very little informations about antibody mediated cellular cytotoxicity (AMCC) phenomenon, after rituximab binding to B cell CD20 receptor molecules, during biological therapy. The patients which showed incomplete B cell depletion, upon rituximab treatment, must receive an extra dose of this biological drug (18-23).

In this article is represented and discussed the obtained results of flow cytometric immunophenotyping analysis of serum specimens taken from clinically selected SLE and RA patients, under RTX therapy. The main goal of our investigations was possible determination of specific molecular markers for individual clinical management improvement if these autoimmune diseases. Out of 10 samples, 4 samples showed significantly lower number of CD19 B lymphocytes, 4 samples showed higher number of this investigated parameter while 2 of them have value within the referral boundaries. On the contrary, majority of samples showed normal values for CD16+56 (60%). Four samples showed lower number of it with accent on sample 9 and 10 which showed seriously reduced number of this parameter.

Out of 5 samples selected for biological therapy sample 1 showed increased number of CD19+ parameter while sample 3 showed slightly lower number of it. Other samples had values within the referral limit. On the other side, just one sample had slightly reduced number regarding CD16+56 investigated parameter.

In both cases, SLE and RA patients, reduced number of CD16+ parameter indicates lower cytotoxic activity of NK cells. Those kind of NK cells have reduced ability of binding with immune complex connected with antigens and therefore their ADCC activity is reduced. Increased number of B cells indicates higher pathological activity leading to severe autoimmune disease allegation. This is the one of first evaluation of NK cells as biomarkers of clinical response after rituximab therapy in rheumatic diseases. The results showed lower level of NK cell killing activity. The determined relative percentage of NK cell is strongly in the correlation for their cilling activity.

The finding of low killing activity in relatives and a correlation between their activity and that of their patients support the view that NK cell deficiency is a genetic determinant of SLE. NK cells in SLE may produce insufficient levels of cytokines required for the regulation of IgG production.

B-cell depletion with unconjugated CD20 monoclonal antibody (mAb) is used to treat rheumatoid arthritis and other autoimmune diseases. This treatment cause depletion mature B cells through monocyte-mediated antibody-dependent cellular cytotoxicity. On the other hand, there is anti-CD19 monoclonal antibodies for therapeutic reduction of B lymphocytes. These humanized re-
Expression of NK (CD16+/56+) and B cells (CD19) Receptor Molecules as a Reliable Clinical Response Biomarkers

combinant antibodies start used in clinical trials from 2009. and offer new possibilities in B-cell depletion therapeutic effects in treatment of SLE and RA (24-27).

6. CONCLUSION

Determining the proportion of NK and B will be useful diagnostic tool in therapeutic strategy, and also in monitoring of effect of biological therapy.

• **Declaration of patient consent:** The authors certify that they have obtained all appropriate patient consent forms.

• **Author’s contribution:** L.Z., M.M. and Dj.S. gave substantial contribution to the conception or design of the work and in the acquisition, analysis and interpretation of data for the work. Each author had role in drafting the work and revising it critically for important intellectual content. E.B. gave final approval of the version to be published and they agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

• **Conflicts of interest:** There are no conflicts of interest.

• **Financial support and sponsorship:** Nil.

REFERENCES

1. Cooper MA, Fehniger TA, Caligiuri MA. The biology of human natural killer-cell subsets. Trends Immunol. 2001; 22: 633-640.

2. Strand V, Kimberly R, Isaacs JD. Biologic therapies in rheumatology: lessons learned, future directions. Nat Rev Drug Discov. 2007; 6: 75-92.

3. Smolen JS, Keystone EC, Emery P, et al. Consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann Rheum Dis. 2007; 66: 143-150.

4. Toubi E, Kessel A, Slobodin G, et al. Changes in macrophage function after rituximab treatment in patients with rheumatoid arthritis. Ann Rheum Dis. 2007; 66: 818-820.

5. Fauschou M, Jayne DR. Anti-B cell antibody therapies for inflammatory rheumatic diseases. Annu Rev Med. 2014; 65: 263-278.

6. Vital EM, Dass S, Buch MH, et al. An extra dose of rituximab improves clinical response in rheumatoid arthritis patients with initial incomplete B cell depletion: a randomised controlled trial. Ann Rheum Dis. 2015; 74(6): 1195-1201.

7. Anolik JH, Campbell D, Felgar RE, et al. The relationship of Fc gamma RIIIA genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus. Arthritis Rheum. 2003; 48(2): 455-459.

8. Vivier E, Raulet DH, Moretta A, et al. Innate or adaptive immunity? The example of natural killer cells. Science. 2011; 331(6013): 44-49.

9. Venkatachalam V, Morrissey P. Cellular image analysis and imaging by flow cytometry. Clin. Lab. Med. 2007; 27(3): 653-670.

10. Lo K, Brinkman RR, Gottardo R. Automated gating of flow cytometry data via robust model-based clustering. Cytometry A. 2008; 73(4): 321-332.

11. FACS MultiSET System (PDF). Becton Dickinson. Archived from the original (PDF) on October 18, 2006. Retrieved 2007-02-09.

12. Kohrt HE, Houot R, Weiskopf K, et al. Stimulation of natural killer cells with a CD137-specific antibody enhances trastuzumab efficacy in xenotransplant models of breast cancer. J Clin Invest. 2012; 122(3): 1066-1075.

13. Carton G, Dacheux L, Salles G, et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor Fc gamma RIIIA gene. Blood. 2002; 99(3): 754-758.

14. Teunen SP, Hansen M, Branagan AR, et al. Polymorphisms in Fc gamma RIIA (CD16) receptor expression are associated with clinical response to rituximab in Waldenstrom’s macroglobulinemia. J Clin Oncol. 2005; 23(3): 474-481.

15. Veeramani S, Wang SY, Dahle C, et al. Rituximab infusion induces NK activation in lymphoma patients with the high-affinity CD16 polymorphism. Blood. 2011; 118(12): 3347-3349.

16. Laurati A, Bertani L, Marazza M, et al. NK cell count as predictor of clinical response in patients with rheumatoid arthritis treated with rituximab. Biologics, 2012; 6: 83-87.

17. Miyake S, Yamamura T. NKT cells and autoimmune diseases: unraveling the complexity. Curr Top Microbiol Immunol. 2007; 314: 251-267.

18. Tedder TF. CD19: a promising B cell target for rheumatoid arthritis. Nat Rev Rheumatol 2009; 5: 572-577.

19. Green MR, Kennell AS, Larche MJ, Seifert MH, Isenberg DA, Salaman MR. Natural killer cell activity in families of patients with systemic lupus erythematosus: demonstration of a killing defect in patients. Clin Exp Immunol. 2005; 141(1): 165-173.

20. Breedveld F, Agarwal S, Yin M, et al. Rituximab pharmacokinetics in patients with rheumatoid arthritis: B-cell levels do not correlate with clinical response. J Clin Pharmacol. 2007; 47(9): 1119-1128.

21. Bowles JA, Wang SY, Link BK, et al. Anti-CD20 monoclonal antibody with enhanced affinity for CD16 activates NK cells at lower concentrations and more effectively than rituximab. Blood. 2006; 108(8): 2648-2654.

22. Edwards JC, Szczepanski L, Szechinski J, et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med. 2004; 350(25): 2572-2581.

23. Reis EA, Athanazio DA, Lima I, et al. NK and NKT cell dynamics after rituximab therapy for systemic lupus erythematosus and rheumatoid arthritis. Rheumatol Int. 2009; 29(4): 479-487.

24. Bowles JA, Wang SY, Link BK, et al. Anti-CD20 monoclonal antibody with enhanced affinity for CD16 activates NK cells at lower concentrations and more effectively than rituximab. Blood. 2006; 108: 2648-2654.

25. Silverman GJ. Therapeutic B cell depletion and regeneration in rheumatoid arthritis: emerging patterns and paradigms. Arthritis Rheum. 2006 Aug; 54(8): 2356-2367.

26. Edwards JC, Szczepanski L, Szechinski J, et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med. 2004; 350(25): 2572-2581.

27. Mendes R, Bromelow KW, Westby M, et al. Flow cytometric visualization of cytokine production by CD3+CD56+ NK cells and CD3+CD56+NKT cells in whole blood. Cytometry. 2000; 39(1): 72-78.